Evidence map›Paper›PMID 24489642›Full record

ArticlePloS one2014

A general method for site specific fluorescent labeling of recombinant chemokines.

Tetsuya Kawamura, Bryan Stephens, Ling Qin, Xin Yin, Michael R Dores, Thomas H Smith, Neil Grimsey, Ruben Abagyan, Joann Trejo, Irina Kufareva and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Tetsuya KawamuraSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
Bryan StephensSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America ; Biomedical Sciences Graduate Program, School of Medicine, University of California San Diego, La Jolla, California, United States of America.
Ling QinSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
Xin YinMarine Drug Research Institute, Huaihai Institute of Technology, Lianyungang, China ; Veterans Affairs San Diego Healthcare System, San Diego, California, United States of America ; Department of Medicine, Division of Pulmonary and Critical Care, University of California San Diego, La Jolla, California, United States of America.
Michael R DoresDepartment of Pharmacology, University of California San Diego, La Jolla, California, United States of America.
Thomas H SmithBiomedical Sciences Graduate Program, School of Medicine, University of California San Diego, La Jolla, California, United States of America ; Department of Pharmacology, University of California San Diego, La Jolla, California, United States of America.
Neil GrimseyDepartment of Pharmacology, University of California San Diego, La Jolla, California, United States of America.
Ruben AbagyanSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
Joann TrejoDepartment of Pharmacology, University of California San Diego, La Jolla, California, United States of America.
Irina KufarevaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
Mark M FusterVeterans Affairs San Diego Healthcare System, San Diego, California, United States of America ; Department of Medicine, Division of Pulmonary and Critical Care, University of California San Diego, La Jolla, California, United States of America.
Catherina L SalangaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
Tracy M HandelSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America.
University of California, San Diego · USJiangsu Ocean University · CNUniversity of California System · US

Funding

UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
Siglec Modulation of Inflammation in Humans and MiceP01HL057345 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, AJIT P · 1997 to 2012
$24.1M
Project 3U54GM094618 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI STEVENS, RAYMOND C · 2010 to 2014
$17.1M
GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
Training In Cardiovascular Physiology & PharmacologyT32HL007444 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen, Robert Scott Ross · 1985 to 2026
$11.1M
MOLECULAR BIOPHYSICS TRAINING PROGRAMT32GM008326 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOMIVES, ELIZABETH A. · 1989 to 2020
$7.5M
STRUCTURE OF MACROPHAGE CHEMOTACTIC ACTIVATING PROTEINSR01AI037113 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M · 1995 to 2015
$5.2M
Structure, Dynamics and Activation Mechanisms of Chemokine ReceptorsU01GM094612 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHANCE, MARK R · 2010 to 2014
$4.5M
Macromolecular DockingR01GM071872 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ABAGYAN, RUBEN · 2004 to 2017
$4.2M
Mechanisms Regulating GPCR TraffickingR01GM090689 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2010 to 2018
$2.9M
Training in Respiratory Biology: Innovate, Integrate, and TranslateT32HL098062 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POWELL, FRANK L. · 2010 to 2014
$2.1M
Lymphatic Microenvironment: Altering Cell Traffic by Targeting GlycansR01HL107652 · NHLBI · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI FUSTER, MARK M · 2012 to 2015
$1.2M
BLRD VA I01 BX000987NHLBI NIH HHS P01 HL057345NHLBI NIH HHS P01 HL57345-14NHLBI NIH HHS R01 HL107652NHLBI NIH HHS R01-HL107652-01A1NHLBI NIH HHS T32 HL007444NHLBI NIH HHS T32 HL098062NHLBI NIH HHS T32-HL098062-03NIAID NIH HHS R01 AI037113NIAID NIH HHS R01 AI37113NIGMS NIH HHS IRACDA NIH K12 GM06852NIGMS NIH HHS K12 GM068524NIGMS NIH HHS NIH R01 GM090689NIGMS NIH HHS R01 GM071872NIGMS NIH HHS R01 GM090689NIGMS NIH HHS T32 GM007752NIGMS NIH HHS T32-GM007752NIGMS NIH HHS T32 GM008326NIGMS NIH HHS U01 GM094612NIGMS NIH HHS U54 GM094618
6 · The paper itself

Abstract

Chemokines control cell migration in many contexts including development, homeostasis, immune surveillance and inflammation. They are also involved in a wide range of pathological conditions ranging from inflammatory diseases and cancer, to HIV. Chemokines function by interacting with two types of receptors: G protein-coupled receptors on the responding cells, which transduce signaling pathways associated with cell migration and activation, and glycosaminoglycans on cell surfaces and the extracellular matrix which organize and present some chemokines on immobilized surface gradients. To probe these interactions, imaging methods and fluorescence-based assays are becoming increasingly desired. Herein, a method for site-specific fluorescence labeling of recombinant chemokines is described. It capitalizes on previously reported 11-12 amino acid tags and phosphopantetheinyl transferase enzymes to install a fluorophore of choice onto a specific serine within the tag through a coenzyme A-fluorophore conjugate. The generality of the method is suggested by our success in labeling several chemokines (CXCL12, CCL2, CCL21 and mutants thereof) and visualizing them bound to chemokine receptors and glycosaminoglycans. CXCL12 and CCL2 showed the expected co-localization on the surface of cells with their respective receptors CXCR4 and CCR2 at 4 °C, and co-internalization with their receptors at 37 °C. By contrast, CCL21 showed the presence of large discrete puncta that were dependent on the presence of both CCR7 and glycosaminoglycans as co-receptors. These data demonstrate the utility of this labeling approach for the detection of chemokine interactions with GAGs and receptors, which can vary in a chemokine-specific manner as shown here. For some applications, the small size of the fluorescent adduct may prove advantageous compared to other methods (e.g. antibody labeling, GFP fusion) by minimally perturbing native interactions. Other advantages of the method are the ease of bacterial expression, the versatility of labeling with any maleimide-fluorophore conjugate of interest, and the covalent nature of the fluorescent adduct.

Indexed as

Cell LineChemokine CCL2Chemokine CCL21Chemokine CXCL12ChemokinesHumansReceptors, CCR2Receptors, CCR7Receptors, CXCR4Recombinant ProteinsCCR2 protein, humanCCR7 protein, humanChemokine CCL2Chemokine CCL21Chemokine CXCL12ChemokinesCXCR4 protein, humanReceptors, CCR2Receptors, CCR7Receptors, CXCR4Recombinant Proteins

Identifiers

PMID24489642
PMCPMC3904831
OpenAlexW2025202081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.